^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 positive

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    4d
    A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Sheba Medical Center | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2026
    Enrollment open • Trial initiation date
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive
    6d
    AMC-112: Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, AIDS Malignancy Consortium | Trial completion date: Jan 2027 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    8d
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 positive
    |
    PIT565
    11d
    Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors (clinicaltrials.gov)
    P1, N=19, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P1 trial
    |
    CD19 positive
    15d
    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (clinicaltrials.gov)
    P1, N=64, Recruiting, Baylor College of Medicine | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    1m
    ELiPSE-1: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (clinicaltrials.gov)
    P1, N=28, Terminated, Century Therapeutics, Inc. | Trial completion date: Aug 2027 --> Jul 2025 | Active, not recruiting --> Terminated; Strategic decision
    Trial completion date • Trial termination
    |
    CD19 positive
    |
    CNTY-101
    2ms
    Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Jul 2026 | Trial primary completion date: Sep 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    CD19 CAR T cells
    2ms
    Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=35, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Nov 2025 | Trial primary completion date: Jun 2026 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    lenalidomide • Blincyto (blinatumomab)
    2ms
    NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy (clinicaltrials.gov)
    P1, N=12, Completed, National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting --> Completed | N=18 --> 12
    Trial completion • Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    CD19 positive
    |
    Hyleukin-7 (efineptakin alfa)
    2ms
    Cell-based potency assay for anti-CD3-anti-CD19 diabody. (PubMed, J Immunol Methods)
    This novel assay met GMP/GLP compliance, allowing a quantifiable and reproducible measure of efficacy, ensuring batch-to-batch consistency, and met safety and effectiveness regulatory requirements. This potency assay may be applicable for testing other CD3-CD19 T cell engagers and suitable for developing other diabody mediated potency assays with appropriate antigens.
    Journal
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    Blincyto (blinatumomab)
    3ms
    Multimodal radiomics machine learning model for predicting the prognosis of lung adenocarcinoma bone metastasis and analysis of traditional Chinese medicine usage patterns (ChiCTR2500110817)
    P=N/A, N=150, Recruiting, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Longhua Hospital Affiliated to Shanghai University of Traditional
    New trial
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    CD19 positive
    3ms
    Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies (ChiCTR2500110470)
    P=N/A, N=19, Not yet recruiting, The First Affiliated Hospital of the University of Science and Technology of China; The First Affiliated Hospital of the University of Science and Tec
    New trial
    |
    CD19 positive